We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed phase 2b data on roflumilast foam presented at AAD VMX 2021.
Gelfand told Healio that roflumilast foam, a topical PDE4 inhibitor, uses a mechanism of action new in the treatment of psoriasis that was previously used in treatments for COPD.
“This is a very exciting therapeutic option if it gets approved by [the] FDA because essentially, it would allow us to treat a variety of areas of the body, from the scalp, inverse areas, genital psoriasis, things of that nature, as data continues to emerge about its efficacy and safety in those areas,” he said.
He added that roflumilast would not have the same adverse events associated with steroids, such as atrophy of the skin.
According to Gelfand, “this is a potentially major breakthrough for the management of psoriasis topically.”
